Tengion (TNGN) (NASDAQ:TNGN) is a pharmaceutical company developing functional neo-organs using a patient's own cells. Neo-organs are replacement organs. The lead product candidate is the Neo-Urinary Conduit. This product is a catalyst that regenerates urinary bladder tissue, targeting bladder cancer patients who had their bladder removed. On 10 March 2010, the company commenced Phase I trials on bladder cancer patient. 
The company also has the product candidate Neo-Bladder Augment for the treatment of neurogenic bladder. This is a dysfunctional bladder due to some neurological disease. This product is in Phase II. There is a large market for treatments of bladder cancer. According to the National Cancer Institute, bladder cancer is the sixth most common cancer with 10,000 cases each year requiring bladder removal. 
The company's initial public offering of stock filed on the NASDAQ and went public on 08 April 2010. The stock was priced at $5.00, below the IPO range of $8.00-$10.00. The company raised $30 million by selling 6 million shares. 
This company is a pre-revenue and is developing its product to enter the market soon.